Oxford Biomedica Past Earnings Performance

Past criteria checks 0/6

Oxford Biomedica's earnings have been declining at an average annual rate of -62.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 9.6% per year.

Key information

-62.7%

Earnings growth rate

-57.9%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate9.6%
Return on equity-235.7%
Net Margin-146.0%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?

Oct 19
Is Oxford Biomedica (LON:OXB) Using Debt Sensibly?

Oxford Biomedica plc (LON:OXB) Not Doing Enough For Some Investors As Its Shares Slump 28%

Aug 23
Oxford Biomedica plc (LON:OXB) Not Doing Enough For Some Investors As Its Shares Slump 28%

Is Oxford Biomedica plc (LON:OXB) Expensive For A Reason? A Look At Its Intrinsic Value

Feb 15
Is Oxford Biomedica plc (LON:OXB) Expensive For A Reason? A Look At Its Intrinsic Value

Is Oxford Biomedica (LON:OXB) Using Too Much Debt?

Oct 06
Is Oxford Biomedica (LON:OXB) Using Too Much Debt?

Investors Shouldn't Be Too Comfortable With Oxford Biomedica's (LON:OXB) Robust Earnings

May 02
Investors Shouldn't Be Too Comfortable With Oxford Biomedica's (LON:OXB) Robust Earnings

We're Not Worried About Oxford Biomedica's (LON:OXB) Cash Burn

Jun 29
We're Not Worried About Oxford Biomedica's (LON:OXB) Cash Burn

Revenue & Expenses Breakdown

How Oxford Biomedica makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:OXB Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2497-1422581
31 Mar 2493-1502592
31 Dec 2390-15725103
30 Sep 23104-11025110
30 Jun 23119-6225117
31 Mar 23130-5024106
31 Dec 22140-392395
30 Sep 22133-322182
30 Jun 22126-251969
31 Mar 22134-31758
31 Dec 21143191447
30 Sep 21139191341
30 Jun 21135191334
31 Mar 2111161237
31 Dec 2088-61140
30 Sep 2077-91239
30 Jun 2066-131338
31 Mar 2065-141234
31 Dec 1964-161230
30 Sep 1964-121026
30 Jun 1964-8922
31 Mar 19650820
31 Dec 18678719
30 Sep 18624722
30 Jun 18570725
31 Mar 1847-5723
31 Dec 1738-9722
30 Sep 1734-10622
30 Jun 1731-11522
31 Mar 1729-14623
31 Dec 1628-17624
30 Sep 1626-16724
30 Jun 1624-16824
31 Mar 1620-15722
31 Dec 1516-13720
30 Sep 1515-12620
30 Jun 1513-10519
31 Mar 1513-9418
31 Dec 1414-9417
30 Sep 1411-9415
30 Jun 148-10314
31 Mar 147-11314
31 Dec 135-11314

Quality Earnings: OXB is currently unprofitable.

Growing Profit Margin: OXB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: OXB is unprofitable, and losses have increased over the past 5 years at a rate of 62.7% per year.

Accelerating Growth: Unable to compare OXB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OXB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: OXB has a negative Return on Equity (-235.75%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies